Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US Business Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US The National Reader June 4, 2022 OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals...Read More
The National Reader